

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: Yoshihiro Sowa et al.

Art Unit : Unknown

Serial No.: 09/937,162

Examiner: Unknown

Filed

: September 21, 2001

Title

: METHOD FOR SCREENING ANTICANCER AGENT

Box PCT

Commissioner for Patents Washington, D.C. 20231

INFORMATION DISCLOSURE STATEMENT

Applicants submit the references listed on the attached form PTO-1449, copies of which references are enclosed.

This statement is being filed within three months of the filing date of the application or before the receipt of a first Office action on the merits. Please apply any charges or credits to Deposit Account No. 06-1050.

Respectfully submitted,

Janis K. Fraser, Ph.D.,

Reg. No. 34,819

Fish & Richardson P.C. 225 Franklin Street

Boston, Massachusetts 02110-2804

Telephone: (617) 542-5070 Facsimile: (617) 542-8906

20392808.doc

CERTIFICATE OF MAILING BY EXPRESS MAIL

Express Mail Label No. EL624270644US

I hereby certify under 37 CFR §1.10 that this correspondence is being deposited with the United States Postal Service as Express Mail Post Office to Addressee with sufficient postage on the date indicated below and is addressed to the Commissioner for Patents, Washington, D.C. 20231.

Date of Deposit

Signature

Typed or Printed Name of Person Signing Certificate

	Substitute Form PTO-1449 (Modified)	U.S. Department of Commerce Patent and Trademark Office	Attorney's Docket No. 06501-085001	Application No. 09/937,162	
	Information Disclosure Statement by Applicant (Use several sheets if necessary) (37 CFR §1.98(b))		Applicant Yoshihiro Sowa et al.		
			Filing Date September 21, 2001	Group Art Unit	

U.S. Patent Documents							
Examiner Initial	Desig. ID	Patent Number	Issue Date	Patentee	Class	Subclass	Filing Date If Appropriate
_	AA						
	AB						
-	AC						
	AD						
	AE						

Foreign Patent Documents or Published Foreign Patent Applications								
Examiner Initial	Desig. ID	Document Number	Publication Date	Country or Patent Office	Class	Subclass	Trans Yes	lation No
	AF	60-149520	08/07/1985	Japan			(Abstr	act
	AG							
	AH							
	AI							

	Other Documents (include Author, Title, Date, and Place of Publication)				
Examiner	Desig.				
Initial	ID	Document			
	AJ	Datto et al., "Functional Analysis of the Transforming Growth Factor β Responsive Elements in the WAF1/Cip1/p21 Promoter", J. Biol. Chem., 270:28623-28628, 1995			
	AK	Nakajima et al., "FR901228, a Potent Antitumor Antibiotic, Is a Novel Histone Deacetylase Inhibitor", Exp. Cell Res., 241:126-133, 1998			
	AL	Nakano et al., "Butyrate Activates the <i>WAF1/Cip1</i> Gene Promoter through Sp1 Sites in a p53-negative Human Colon Cancer Cell Line", J. Biol. Chem., 272:22199-22206, 1997			
	AM	Sowa et al., "Sp3, but not Sp1, Mediates the Transcriptionsl Activation of the p21/WAF1/Cip1 Gene Promoter by Histone Deacetylase Inhibitor", Cancer Res., 59:426604270, 1999			
	AN	Sowa et al., "Histone Deacetylase Inhibitor Activates the WAF1/Cip1 Gene Promoter through the Sp1 Sites", Biochem. Biophys. Res. Commun., 241:142-150, 1997			
	AO	Warrell, Jr., et al., "Therapeutic Targeting of Transcription in Acute Promyelocytic Leukemia by Use of an Inhibitor of Histone Deacetylase", J. Nat'l. Cancer Inst., 90:1621-1625, 1998			
	AP	Xiao et al., "Both Sp1 and Sp3 Are Responsible for p21 ^{waf1} Promoter Activity Induced by Histone Deacetylase Inhibitor in NIH3T3 Cells", J. Cellular Biochem., 73:291-302, 1999			
	AQ	Yoshida et al., "Potent and Specific Inhibition of Mammalian Histone Deacetylase Both <i>in Vivo</i> and <i>in Vitro</i> by Trichostatin A", J. Biol. Chem., 265:17174-17179, 1990			
	AR				
	AS				

Examiner Signature	Date Considered
EXAMINER: Initials citation considered. Draw line through citation if no next communication to applicant.	t in conformance and not considered. Include copy of this form with